Screener
Beam Therapeutics BEAM Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| License and collaboration revenue | $31,738 | $7,470 |
| Operating expenses: | ||
| Research and development | 104,524 | 98,816 |
| General and administrative | 34,429 | 27,940 |
| Total operating expenses | 138,953 | 126,756 |
| Loss from operations | (107,215) | (119,286) |
| Other income (expense): | ||
| Change in fair value of derivative liabilities | 2,500 | 3,200 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's total revenue?
- Beam Therapeutics (BEAM) reported total revenue of $31.74M in Q1 2026.
- How has Beam Therapeutics's total revenue changed year-over-year?
- Beam Therapeutics's total revenue increased by 324.9% year-over-year, from $7.47M to $31.74M.
- What is the long-term trend for Beam Therapeutics's total revenue?
- Over 4 years (2021 to 2025), Beam Therapeutics's total revenue has grown at a 28.1% compound annual growth rate (CAGR), from $51.84M to $139.74M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Beam Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude